To date, the expression of programmed death ligand 1 (PD-L1) in tumor tissue remains the most available biomarker to assess patients for treatment with anti-PD1/PD-L1 therapy, although it is not generally considered as an optimal parameter. This evidence concerns the gene CD274 and neoplasm.